NEW YORK (GenomeWeb) – 908 Devices today announced that it has raised an additional $1.4 million as part of a Series C round of financing, bringing the total raised in the round to $13 million.
The latest fundraising included investments from Casdin Capital, as well as Ortho Clinical Diagnostics Chairman and CEO Martin Madaus and former Thermo Fisher Scientific Chairman Paul Meister, among others.
In May, the company said that it raised $11.6 million in a round led by Saudi Aramco Energy Ventures, the corporate venturing subsidiary of Saudi Arabia's national oil company. Also participating were existing investors Arch Venture Partners, Razor's Edge Ventures, University of Tokyo Edge Capital, international oilfield service firm Schlumberger, as well as certain individual investors.
In total, 908 Devices has raised $29 million.
The company said the Series C capital would be used to expand commercialization efforts around its M908 miniature mass spectrometry device, as well as develop the product for new applications in the oil and gas, environmental, and life science markets.